ABL Bio said on the 19th that the U.S. Food and Drug Administration (FDA) approved the phase 1 investigational new drug (IND) application for its bispecific Antibody-Drug Conjugate (ADC) candidate ...

SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for ...

The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...

First announced all the way back in 2022, Behringer's UB-1 is an Oberheim-inspired microsynth based on the 3396/3397 chip design found in the company's Matrix synths. Since then, Behringer has ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

Eli Lilly's $2.6 billion agreement with ABL Bio focuses on developing therapeutics using the Grabody Platform for bispecific antibodies. ABL Bio will receive an upfront payment and potential milestone ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

ABL Bio said on the 12th that it signed a technology transfer and joint research and development agreement with U.S.-based Eli Lilly for the "Grabody-B" platform, a technology that penetrates the ...

Behringer has announced the release of BQ-10, an analogue semi-modular sequencer based on the classic Korg SQ-10. Having first teased BQ-10 all the way back in 2023, Behringer has made the instrument ...